Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TCT 2018: Abbott Expects COAPT Results To Support Expanding MitraClip's Indication

Executive Summary

Data presented at the Transcatheter Cardiovascular Therapeutics conference Sept. 23 in San Diego will support expanding the label of Abbott's MitraClip mitral valve repair device to include secondary, or functional, mitral regurgitation, a company executive tells Medtech Insight. In the COAPT trial, MitraClip reduced the two-year rate of heart-failure hospitalization and all-cause mortality in patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation.

You may also be interested in...



CMS Proposes Coverage Policy For Transcatheter Edge-to-Edge Mitral Valve Repair

In a new draft National Coverage Determination, the US Medicare agency proposes extending coverage of transcatheter mitral valve repair to certain patients with functional mitral regurgitation.

TCT 2019: New COAPT Results Support, Durability And Cost-Effectiveness Of Abbott’s MitraClip

The three-year results from the COAPT trial confirm Abbott’s MitraClip transcatheter mitral valve replacement device can improve the prognosis of functional heart failure patients. A separate analysis of COAPT showed MitraClip is cost-effective compared to medical therapy.

Functional MR Added To FDA-Approved Indication For Abbott's MitraClip

The new indication covers functional mitral regurgitation, also known as secondary mitral regurgitation, which represents two-to-three times as many patients as the primary mitral regurgitation population MitraClip is already labeled for. The approval is supported by results from the COAPT trial, the first randomized trial to show that a mitral-valve repair could improve outcomes in patients with secondary mitral regurgitation.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT123311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel